ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L10

Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)

Sarah Julien1, Emma Briand1, Bas van der Woning2, Leentje de ceuninck3, Rachid zoubari1, olivier benveniste4, laurent drouot1 and olivier boyer5, 1INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, 2argenx, Boston, MA, 3argenx, Ghent, Belgium, 4AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, 5INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France

Meeting: ACR Convergence 2022

Date of first publication: October 18, 2022

Keywords: autoimmune diseases, immunology, Late-Breaking 2022, Mouse Models, Other, Muscle strength, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: (L07–L17) Late-Breaking Abstract Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent autoantibody (aAb) in IMNM patients is directed against hydroxymethylglutaryl-Coenzyme A reductase (HMGCR). Anti-HMGCR aAb are pathogenic and induce disease after adoptive transfer to mice by two separate mechanisms: 1) myolysis following complement activation; and 2) impairment of muscle fiber regeneration. Efgartigimod is an IgG1 Fc fragment targeting the neonatal Fc receptor (FcRn). We evaluated the therapeutic effects of IgG clearance by efgartigimod in a humanized murine model of IMNM.

Methods: Groups of Rag2 deficient (Rag2-/-) mice received daily intraperitoneal injections of IgG-depleted human serum as a source of human complement. Disease was induced by injections of 2 mg IgG purified from an anti-HMGCR aAb+ IMNM patient or from a healthy donor as control (day 0, 4 ±day 8, 12, 16). Rag2-/- mice were treated with efgartigimod in a curative setting (day 8, 11, 15) after disease was induced by IgG injections. Muscle force was assessed by grip test or measurement of gastrocnemius strength upon sciatic nerve electrostimulation (anesthetized animals). Levels of total IgG or anti-HMGCR+ IgG aAb were monitored in mouse serum by ELISA and ALBIA, respectively. Histological analysis of muscle tissue sections was performed after staining with hematoxylin/eosin or fluorochrome-labeled antibodies.

Results: In a therapeutic setting, administration of efgartigimod fully restored grip strength and muscle strength in mice treated with pathogenic anti-HMGCR+ IgG (p < 0.05). Total IgG and specific anti-HMGCR+ IgG aAb became undetectable in serum since day 18, i.e. 9 days after efgartigimod administration. Histological analyses demonstrated that efgartigimod reduces IgG deposits, prevents further necrosis and allows for muscle fiber regeneration.

Conclusion: Efgartigimod dramatically reduces circulating IgG levels and rapidly eliminates pathogenic anti-HMGCR+ in a humanized mouse model of IMNM, preventing further necrosis and allowing muscle fiber regeneration, resulting in regain of muscle performance. These results support investigating the therapeutic efficacy of efgartigimod through a clinical trial in IMNM patients.

Supporting image 1

Efgartigimod treatment reduces anti-HMGCR titers in passive transfer model for IMNM. A. treatment scheme. B. Anti-HMGCR titers monitored in mouse serum by ALBIA.

Supporting image 2

Efgartigimod restores grip strength in mice that lost grip strength due to pathogenic anti-HMGCR. Therapeutic treatment with efgartigimod SC as of day 8, after onset of disease.

Supporting image 3

Efgartigimod allows regeneration of muscle fibers in anti-HMGCR affected mice. A. H&E staining showing necrotic and regenerating muscle fibers. Cells with the nucleus in the middle of the cell (often show multiple nuclei) are markers of muscle fiber regeneration. B. Quantification of necrotic and regenerating muscle fibers.


Disclosures: S. Julien, None; E. Briand, None; B. van der Woning, argenx; L. de ceuninck, argenx; R. zoubari, None; o. benveniste, Sanofi, AFM; l. drouot, None; o. boyer, Argenx, Bristol-Myers Squibb(BMS), CSL Behring, Egle Tx, UCB.

To cite this abstract in AMA style:

Julien S, Briand E, van der Woning B, de ceuninck L, zoubari R, benveniste o, drouot l, boyer o. Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/efgartigimod-prevents-necrosis-and-allows-for-muscle-fiber-regeneration-in-a-humanized-mouse-model-of-immune-mediated-necrotizing-myopathy-imnm/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efgartigimod-prevents-necrosis-and-allows-for-muscle-fiber-regeneration-in-a-humanized-mouse-model-of-immune-mediated-necrotizing-myopathy-imnm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology